Treatment with cetuximab (Erbitux) was less effective for patients with advanced colorectal cancer with a certain gene mutation, a new study found. Scientists already knew that the presence of K-ras mutations explains about 30 to 40 percent of cases in which colorectal cancer patients fail to respond to Erbitux, developed by ImClone and sold by Bristol-Myers Squibb and Merck KGaA, and Vectibix, from Amgen. The latest findings added another 12 percent.
Read the rest of this entry »
January 13th, 2009 | Posted in Colorectal Cancer, News | Tags: cancer, Colon, Effective, Erbitux, Gene, less, Mutation, patients, Second, with
Women who confront with migraines stand less chance of developing breast cancer, according to researchers from the Fred Hutchinson Cancer Research Center in Seattle.
This correlation may be related to estrogen, a hormone produced in both men and women. The explanation goes like that: high levels of estrogen are linked to an augmented risk of breast cancer, and women who experience migraines are said to have low levels of the sex hormone. So these women have a lower risk of developing breast cancer. More precisely, the risk is 30 percent lower, researchers say.
Read the rest of this entry »
January 12th, 2009 | Posted in Breast Cancer, News | Tags: breast, cancer, Chances, Developing, less, Migraines, More